Kaveh Pourhamidi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kaveh Pourhamidi has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Lars B. Dahlin
Hand Surgery, Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden
5 shared publicationsOlov Rolandsson
Family Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
5 shared publications- Elisabet Englund
Division of Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden
2 shared publications Hanna Skärstrand
Department of Clinical Sciences Malmö, Unit of Diabetes and Celiac Diseases, Skåne University Hospital, 205 02 Malmö, Sweden
2 shared publications- Malin Zimmerman
Department of Translational Medicine—Hand Surgery, Lund University, Skåne University Hospital, Malmö, Sweden
2 shared publications Anders Gottsäter
Department of Vascular Diseases, Skåne University Hospital, 205 02 Malmö, Sweden
1 shared publication
Latest Publications
- Open Access
- 13 December 2024
- Published by Wiley in Muscle & Nerve
- Vol. 71 (2) , 223-228
Non‐Hospitalized Patients With Post‐COVID Condition and Myopathic Electromyography Findings Show no Difference in Symptom Severity and Clinical Manifestations Compared to Those Without Myopathic Findings
Introduction: The COVID‐19 pandemic has resulted in a post‐infectious syndrome designated as long‐COVID or post‐COVID condition (PCC) that presents with numerous symptoms including fatigue and myalgias. This study evaluated myopathic electromyography (EMG) findings in non‐hospitalized PCC patients in relation to symptom severity, quality of life (QoL), and physical function.Methods: Twenty‐nine PCC patients with persistent symptoms ≥ 3 months after laboratory‐confirmed SARS‐CoV‐2 infection, without hospitalization or comorbidities, were included. EMG, nerve conduction studies (NCS), and quantitative sensory testing (QST) were performed. Symptom severity was measured with visual analog scales, QoL with validated questionnaires, and physical function with the 6‐min walk test, cardiopulmonary exercise testing, handgrip strength, and isokinetic dynamometry.Results: Myopathic findings on EMG were present in 62% of PCC patients (n = 18). Symptom severity (muscle pain and fatigue) and QoL (physical function and fatigue) were similar between patients with and without myopathic EMG findings. The 6‐min walk test (457 ± 81 vs. 459 ± 86 m) and peak VO2 (29 ± 9 vs. 28 ± 6 mL/kg/min) were similar between patients with and without myopathic EMG findings. Handgrip strength (32 [29–43] vs. 33 [29–50] kg) and quadriceps muscle strength (136 [111–191] vs. 136 [114–184] Nm) were comparable between the groups. NCS and QST results were normal in all patients.Discussion: Myopathic findings on EMG are common in PCC patients, but no significant differences in symptom severity, QoL, or physical function were found between those with and without myopathic EMG findings. Myopathic EMG changes in PCC patients should be interpreted with caution, considering the overall clinical context.
- 13 December 2024
- Published by Wiley in Muscle & Nerve
- Vol. 71 (2) , 223-228
Open AccessNon‐Hospitalized Patients With Post‐COVID Condition and Myopathic Electromyography Findings Show no Difference in Symptom Severity and Clinical Manifestations Compared to Those Without Myopathic Findings
Introduction: The COVID‐19 pandemic has resulted in a post‐infectious syndrome designated as long‐COVID or post‐COVID condition (PCC) that presents with numerous symptoms including fatigue and myalgias. This study evaluated myopathic electromyography (EMG) findings in non‐hospitalized PCC patients in relation to symptom severity, quality of life (QoL), and physical function.Methods: Twenty‐nine PCC patients with persistent symptoms ≥ 3 months after laboratory‐confirmed SARS‐CoV‐2 infection, without hospitalization or comorbidities, were included. EMG, nerve conduction studies (NCS), and quantitative sensory testing (QST) were performed. Symptom severity was measured with visual analog scales, QoL with validated questionnaires, and physical function with the 6‐min walk test, cardiopulmonary exercise testing, handgrip strength, and isokinetic dynamometry.Results: Myopathic findings on EMG were present in 62% of PCC patients (n = 18). Symptom severity (muscle pain and fatigue) and QoL (physical function and fatigue) were similar between patients with and without myopathic EMG findings. The 6‐min walk test (457 ± 81 vs. 459 ± 86 m) and peak VO2 (29 ± 9 vs. 28 ± 6 mL/kg/min) were similar between patients with and without myopathic EMG findings. Handgrip strength (32 [29–43] vs. 33 [29–50] kg) and quadriceps muscle strength (136 [111–191] vs. 136 [114–184] Nm) were comparable between the groups. NCS and QST results were normal in all patients.Discussion: Myopathic findings on EMG are common in PCC patients, but no significant differences in symptom severity, QoL, or physical function were found between those with and without myopathic EMG findings. Myopathic EMG changes in PCC patients should be interpreted with caution, considering the overall clinical context.
- 21 June 2024
- Published by Wolters Kluwer Health in Journal Of Clinical Neurophysiology
- Vol. 42 (2) , 145-148
Normative Data and Quantile Regression Analysis of the Sural-to-Radial Nerve Amplitude Ratio
Purpose: The aim of this study was to establish normative data for the sural-to-radial nerve amplitude ratio (SRAR) and develop a quantile regression model for individualized cutoff values. Methods: A cohort of 68 healthy individuals (36 female participants) aged 20 to 59 years was recruited. Sensory nerve conduction studies were conducted to measure sural and radial sensory nerve action potential amplitudes. Quantile regression analysis was used to determine the fifth percentile of SRAR after adjusting for age, sex, and other demographic variables. Results: This study found significant differences in body height and weight between the sexes, with radial sensory nerve action potential being higher in female participants. The sural-to-radial nerve amplitude ratio was negatively correlated with age (r = −0.3, p = 0.007) and showed significant sex differences. The final regression equation, SRAR = 0.519 − 0.006 × age + 0.046 × sex (1 = male, 0 = female), was developed for the fifth percentile cutoff, accounting for age and sex. Conclusions: This study establishes normative SRAR data and introduces a novel quantile regression approach to determine individualized cutoff values. Age and sex are critical factors for SRAR variation, necessitating tailored diagnostic criteria for neuropathy assessment. This model enhances diagnostic accuracy and potentially reduces misdiagnosis in clinical settings. Further research is recommended to validate the clinical applicability of SRAR across different types of neuropathies.
- 21 June 2024
- Published by Wolters Kluwer Health in Journal Of Clinical Neurophysiology
- Vol. 42 (2) , 145-148
Normative Data and Quantile Regression Analysis of the Sural-to-Radial Nerve Amplitude Ratio
Purpose: The aim of this study was to establish normative data for the sural-to-radial nerve amplitude ratio (SRAR) and develop a quantile regression model for individualized cutoff values. Methods: A cohort of 68 healthy individuals (36 female participants) aged 20 to 59 years was recruited. Sensory nerve conduction studies were conducted to measure sural and radial sensory nerve action potential amplitudes. Quantile regression analysis was used to determine the fifth percentile of SRAR after adjusting for age, sex, and other demographic variables. Results: This study found significant differences in body height and weight between the sexes, with radial sensory nerve action potential being higher in female participants. The sural-to-radial nerve amplitude ratio was negatively correlated with age (r = −0.3, p = 0.007) and showed significant sex differences. The final regression equation, SRAR = 0.519 − 0.006 × age + 0.046 × sex (1 = male, 0 = female), was developed for the fifth percentile cutoff, accounting for age and sex. Conclusions: This study establishes normative SRAR data and introduces a novel quantile regression approach to determine individualized cutoff values. Age and sex are critical factors for SRAR variation, necessitating tailored diagnostic criteria for neuropathy assessment. This model enhances diagnostic accuracy and potentially reduces misdiagnosis in clinical settings. Further research is recommended to validate the clinical applicability of SRAR across different types of neuropathies.
- 22 April 2024
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 32 (5) , 215-221
Reliable Method for Estimating Nerve Fiber Density in Epidermis Using Routine Histopathologic Tissue Preparation: A Promising Diagnostic Tool for Small Fiber Neuropathy
Practical yet reliable diagnostic tools for small-fiber neuropathy are needed. We aimed to establish a histopathologic protocol for estimating intraepidermal nerve fiber density (eIENFD) on formalin-fixed, paraffin-embedded tissue (FFPE), evaluate its reliability through intraobserver and interobserver analyses, and provide normative reference values for clinical use. Sixty-eight healthy participants underwent nerve conduction studies and quantitative sensory testing. Skin biopsies from the distal and proximal leg were taken and processed using routine immunohistochemistry (anti-PGP9.5 antibodies) on thin 5 µm sections. eIENFD was assessed with a modified counting protocol. Interobserver and intraobserver reliabilities were excellent (ICC=0.9). eIENFD was higher in females than males (fibers/mm, 14.3±4.4 vs. 11.6±5.8, Prs =–0.47, PP=0.002). Quantile regression equations for the fifth percentile of distal and proximal eIENFD were presented: 13.125–0.161×age (y)–0.932×sex (male=1; female=0) and 17.204–0.192×age (y)–3.313×sex (male=1; female=0), respectively. This study introduces a reliable and reproducible method for estimating epidermal nerve fiber density through immunostaining on 5-µm thin FFPE tissue samples. Normative data on eIENFD is provided. Regression equations help identify abnormal decreases in small nerve fiber density.
- 22 April 2024
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 32 (5) , 215-221
Reliable Method for Estimating Nerve Fiber Density in Epidermis Using Routine Histopathologic Tissue Preparation: A Promising Diagnostic Tool for Small Fiber Neuropathy
Practical yet reliable diagnostic tools for small-fiber neuropathy are needed. We aimed to establish a histopathologic protocol for estimating intraepidermal nerve fiber density (eIENFD) on formalin-fixed, paraffin-embedded tissue (FFPE), evaluate its reliability through intraobserver and interobserver analyses, and provide normative reference values for clinical use. Sixty-eight healthy participants underwent nerve conduction studies and quantitative sensory testing. Skin biopsies from the distal and proximal leg were taken and processed using routine immunohistochemistry (anti-PGP9.5 antibodies) on thin 5 µm sections. eIENFD was assessed with a modified counting protocol. Interobserver and intraobserver reliabilities were excellent (ICC=0.9). eIENFD was higher in females than males (fibers/mm, 14.3±4.4 vs. 11.6±5.8, Prs =–0.47, PP=0.002). Quantile regression equations for the fifth percentile of distal and proximal eIENFD were presented: 13.125–0.161×age (y)–0.932×sex (male=1; female=0) and 17.204–0.192×age (y)–3.313×sex (male=1; female=0), respectively. This study introduces a reliable and reproducible method for estimating epidermal nerve fiber density through immunostaining on 5-µm thin FFPE tissue samples. Normative data on eIENFD is provided. Regression equations help identify abnormal decreases in small nerve fiber density.
- Open Access
- 28 October 2021
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 7 (6) , e628
Adult-Onset Ataxia With Neuropathy and White Matter Abnormalities Due to a Novel SAMD9L Variant
- 28 October 2021
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 7 (6) , e628
Open AccessAdult-Onset Ataxia With Neuropathy and White Matter Abnormalities Due to a Novel SAMD9L Variant
- Open Access
- 14 March 2018
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 9, 154
Autonomic Neuropathy—a Prospective Cohort Study of Symptoms and E/I Ratio in Normal Glucose Tolerance, Impaired Glucose Tolerance, and Type 2 Diabetes
Background: Autonomic neuropathy in diabetes, in addition to causing a range of symptoms originating from the autonomic nervous system, may increase cardiovascular morbidity. Our aim was to study the progression of autonomic neuropathy, based on symptom score and evaluation of an autonomic test, in persons with normal and impaired glucose tolerance and in patients with type 2 diabetes (T2D). Methods: Participants were recruited in 2003/2004 with a follow-up in 2014. The participants’ glucose tolerance was categorized using oral glucose tolerance tests. Symptoms were evaluated using an autonomic symptom score (ASS), ECG was used to test cardiac autonomic function based on the expiration/inspiration ratio (E/I ratio), and blood samples were taken on both occasions. Results: ASSs were higher at follow-up in the T2D patients than in the normal glucose tolerance group (mean 1.21 ± 1.30 vs. 0.79 ± 0.7; p < 0.05). E/I ratio did not deteriorate more than could be expected as an aging effect in well-controlled T2D. No relationship was found between E/I ratio and HbA1c or ASS. Conclusion: The presence of autonomic symptoms increased over time in T2D patients, but the symptoms did not correlate with the E/I ratio in this metabolically well-controlled cohort. ASSs can be a useful clinical tool when assessing the progression of autonomic dysfunction in patients with abnormal glucose metabolism.
- 14 March 2018
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 9, 154
Open AccessAutonomic Neuropathy—a Prospective Cohort Study of Symptoms and E/I Ratio in Normal Glucose Tolerance, Impaired Glucose Tolerance, and Type 2 Diabetes
Background: Autonomic neuropathy in diabetes, in addition to causing a range of symptoms originating from the autonomic nervous system, may increase cardiovascular morbidity. Our aim was to study the progression of autonomic neuropathy, based on symptom score and evaluation of an autonomic test, in persons with normal and impaired glucose tolerance and in patients with type 2 diabetes (T2D). Methods: Participants were recruited in 2003/2004 with a follow-up in 2014. The participants’ glucose tolerance was categorized using oral glucose tolerance tests. Symptoms were evaluated using an autonomic symptom score (ASS), ECG was used to test cardiac autonomic function based on the expiration/inspiration ratio (E/I ratio), and blood samples were taken on both occasions. Results: ASSs were higher at follow-up in the T2D patients than in the normal glucose tolerance group (mean 1.21 ± 1.30 vs. 0.79 ± 0.7; p < 0.05). E/I ratio did not deteriorate more than could be expected as an aging effect in well-controlled T2D. No relationship was found between E/I ratio and HbA1c or ASS. Conclusion: The presence of autonomic symptoms increased over time in T2D patients, but the symptoms did not correlate with the E/I ratio in this metabolically well-controlled cohort. ASSs can be a useful clinical tool when assessing the progression of autonomic dysfunction in patients with abnormal glucose metabolism.
- Open Access
- 1 June 2017
- Published by Elsevier in Journal of Clinical & Translational Endocrinology
- Vol. 8, 15-21
Temporal trend of autonomic nerve function and HSP27, MIF and PAI-1 in type 1 diabetes
- 1 June 2017
- Published by Elsevier in Journal of Clinical & Translational Endocrinology
- Vol. 8, 15-21
Open AccessTemporal trend of autonomic nerve function and HSP27, MIF and PAI-1 in type 1 diabetes
- 1 April 2014
- Published by Elsevier in Primary Care Diabetes
- Vol. 8 (1) , 77-84
Evaluation of clinical tools and their diagnostic use in distal symmetric polyneuropathy
- 1 April 2014
- Published by Elsevier in Primary Care Diabetes
- Vol. 8 (1) , 77-84
Evaluation of clinical tools and their diagnostic use in distal symmetric polyneuropathy
- Open Access
- 11 February 2014
- Published by American Diabetes Association in Diabetes Care
- Vol. 37 (3) , e49-e50
HSP27 Concentrations Are Lower in Patients With Type 1 Diabetes and Correlate With Large Nerve Fiber Dysfunction
- 11 February 2014
- Published by American Diabetes Association in Diabetes Care
- Vol. 37 (3) , e49-e50
Open AccessHSP27 Concentrations Are Lower in Patients With Type 1 Diabetes and Correlate With Large Nerve Fiber Dysfunction
- Open Access
- 14 March 2013
- Published by American Diabetes Association in Diabetes Care
- Vol. 36 (4) , 962-964
No Difference in Small or Large Nerve Fiber Function Between Individuals With Normal Glucose Tolerance and Impaired Glucose Tolerance
OBJECTIVE: To assess small and large nerve fiber function in people with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: Participants were recruited consecutively from a population-based cohort: NGT (n = 39), IGT (n = 29), and T2D (n = 51). Electrophysiological measures included nerve conduction studies and thermal thresholds. Intraepidermal nerve fiber density (IENFD) in skin biopsies was calculated. RESULTS: There was no difference between IGT and NGT in sural nerve conduction, IENFD, and thermal thresholds. IENFD was significantly lower in T2D (median = 2.8 fibers/mm [interquartile range 1.1–4.7 fibers/mm]) than NGT individuals (4.5 fibers/mm [3.4–6.1 fibers/mm]; P < 0.05). T2D participants had poorer nerve conduction and higher heat thresholds than NGT and IGT. CONCLUSIONS: Large and small nerve function in people with IGT did not differ from those with NGT. Our finding does not support the existence of neuropathy in a prediabetic stage.
- 14 March 2013
- Published by American Diabetes Association in Diabetes Care
- Vol. 36 (4) , 962-964
Open AccessNo Difference in Small or Large Nerve Fiber Function Between Individuals With Normal Glucose Tolerance and Impaired Glucose Tolerance
OBJECTIVE: To assess small and large nerve fiber function in people with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: Participants were recruited consecutively from a population-based cohort: NGT (n = 39), IGT (n = 29), and T2D (n = 51). Electrophysiological measures included nerve conduction studies and thermal thresholds. Intraepidermal nerve fiber density (IENFD) in skin biopsies was calculated. RESULTS: There was no difference between IGT and NGT in sural nerve conduction, IENFD, and thermal thresholds. IENFD was significantly lower in T2D (median = 2.8 fibers/mm [interquartile range 1.1–4.7 fibers/mm]) than NGT individuals (4.5 fibers/mm [3.4–6.1 fibers/mm]; P < 0.05). T2D participants had poorer nerve conduction and higher heat thresholds than NGT and IGT. CONCLUSIONS: Large and small nerve function in people with IGT did not differ from those with NGT. Our finding does not support the existence of neuropathy in a prediabetic stage.
- 10 September 2011
- Published by Springer Nature in Diabetologia
- Vol. 54 (12) , 3143-3149
Heat shock protein 27 is associated with better nerve function and fewer signs of neuropathy
Aims/hypothesis High levels of serum heat shock protein 27 (sHSP27) have been associated with distal symmetric polyneuropathy in patients with type 1 diabetes. Our objective was to investigate the association between sHSP27, neuropathic signs and nerve function in individuals with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and type 2 diabetes. Methods Participants were recruited consecutively from the population-based Västerbotten Intervention Program (NGT, n = 39, IGT, n = 29, and type 2 diabetes, n = 51) and were matched for age and sex. sHSP27 levels were measured and nerve conduction studies were performed (peroneal and sural nerves). z Scores for each nerve conduction measure were calculated and compiled into a composite z score for the leg. Neuropathy disability score (NDS) was used to assess neuropathic signs. Results Patients with diabetes had significantly lower sHSP27 levels (geometric mean sHSP27 206 pg/ml, 95% CI 142, 299) than those with IGT (geometric mean sHSP27 455 pg/ml, 95% CI 319, 650, p < 0.05) and controls (geometric mean sHSP27 361 pg/ml, 95% CI 282, 461, p < 0.05). Participants with few signs of neuropathy (first tertile, NDS ≤2) had significantly higher sHSP27 levels (geometric mean sHSP27 401 pg/ml, 95% CI 310, 520) than participants with many signs (third tertile, NDS ≥7) (geometric mean sHSP27 192 pg/ml, 95% CI 128, 288, p = 0.007). The highest sHSP27 tertile was associated with better nerve function, adjusted for age, sex, statin medication and HbA1c (OR 2.51, 95% CI 1.25, 5.05, p < 0.05). Conclusions/interpretation High sHSP27 levels were associated with better nerve function and fewer neuropathic signs in NGT, IGT and type 2 diabetes.
- 10 September 2011
- Published by Springer Nature in Diabetologia
- Vol. 54 (12) , 3143-3149
Heat shock protein 27 is associated with better nerve function and fewer signs of neuropathy
Aims/hypothesis High levels of serum heat shock protein 27 (sHSP27) have been associated with distal symmetric polyneuropathy in patients with type 1 diabetes. Our objective was to investigate the association between sHSP27, neuropathic signs and nerve function in individuals with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and type 2 diabetes. Methods Participants were recruited consecutively from the population-based Västerbotten Intervention Program (NGT, n = 39, IGT, n = 29, and type 2 diabetes, n = 51) and were matched for age and sex. sHSP27 levels were measured and nerve conduction studies were performed (peroneal and sural nerves). z Scores for each nerve conduction measure were calculated and compiled into a composite z score for the leg. Neuropathy disability score (NDS) was used to assess neuropathic signs. Results Patients with diabetes had significantly lower sHSP27 levels (geometric mean sHSP27 206 pg/ml, 95% CI 142, 299) than those with IGT (geometric mean sHSP27 455 pg/ml, 95% CI 319, 650, p < 0.05) and controls (geometric mean sHSP27 361 pg/ml, 95% CI 282, 461, p < 0.05). Participants with few signs of neuropathy (first tertile, NDS ≤2) had significantly higher sHSP27 levels (geometric mean sHSP27 401 pg/ml, 95% CI 310, 520) than participants with many signs (third tertile, NDS ≥7) (geometric mean sHSP27 192 pg/ml, 95% CI 128, 288, p = 0.007). The highest sHSP27 tertile was associated with better nerve function, adjusted for age, sex, statin medication and HbA1c (OR 2.51, 95% CI 1.25, 5.05, p < 0.05). Conclusions/interpretation High sHSP27 levels were associated with better nerve function and fewer neuropathic signs in NGT, IGT and type 2 diabetes.